Little is known about the occurrence and predictive factors of autonomic neuropathy and its relationship to cardiovascular mortality in NIDDM patients, and no long-term follow-up studies including nondiabetic control subjects are available. A total of 133 patients with newly diagnosed NIDDM (70 men) and 144 control subjects (62 men) were examined at baseline and after 5 and 10 years of follow-up. Deep-breathing tests (baseline, 5-year, and 10-year) and active orthostatic tests (5- and 10-year) were performed. Criteria for autonomic neuropathy were parasympathetic (expiration-to-inspiration ratio ≤1.10), sympathetic (systolic blood pressure decrease ≥30 mmHg in the orthostatic test), and combined autonomic neuropathy (parasympathetic with sympathetic neuropathy). The frequency of parasympathetic neuropathy (NIDDM patients versus control subjects) was 4.9 vs. 2.2% (P = 0.224) at baseline, 19.6 vs. 8.5% (P = 0.017) at 5 years, and 65.0 vs. 28.0% (P < 0.001) at 10 years of follow-up. The frequency of sympathetic neuropathy was 6.8 vs. 5.6% (P = 0.709) at 5 years and 24.4 vs. 9.0% (P = 0.003) at 10 years of follow-up. These figures for combined autonomic neuropathy were 2.1 vs. 1.8% (P = 0.869) at 5 years and 15.2 vs. 4.2% (P = 0.007) at 10 years of follow-up. NIDDM patients with parasympathetic neuropathy at the 10-year examination showed worse glycemic control and higher insulin values than those without parasympathetic neuropathy. Furthermore, in our subjects, women were more prone to have parasympathetic neuropathy than men. Parasympathetic neuropathy at baseline was more frequent in those who died from a cardiovascular cause than those who did not (13 vs. 3%, P = 0.045). Similarly, sympathetic autonomic nervous dysfunction at the 5-year examination predicted the 10-year cardiovascular mortality. In conclusion, the frequency of autonomic neuropathy in NIDDM patients increases sharply with time. The development of autonomic neuropathy is connected with poor glycemic control. Interestingly, a high insulin level seems to have a predictive role in the development of parasympathetic autonomic neuropathy irrespective of obesity and glycemia.
Original Articles|
March 01 1996
Occurrence, Predictors, and Clinical Significance of Autonomic Neuropathy in NIDDM: Ten-Year Follow-Up From the Diagnosis
Jari P Töyry;
Jari P Töyry
Departments of Clinical Physiology
Kuopio, Finland
Search for other works by this author on:
Leo K Niskanen;
Leo K Niskanen
Kuopio University Hospital
Kuopio, Finland
Search for other works by this author on:
Matti J Mäntysaari;
Matti J Mäntysaari
Departments of Clinical Physiology
Kuopio, Finland
Search for other works by this author on:
Esko A Länsimies;
Esko A Länsimies
Departments of Clinical Physiology
Kuopio, Finland
Search for other works by this author on:
Matti IJ Uusitupa
Matti IJ Uusitupa
Clinical Nutrition and Internal Medicine
Kuopio, Finland
Search for other works by this author on:
Address correspondence and reprint requests to Dr. Jari Toyry, Department of Clinical Physiology, Kuopio University Hospital, Kuopio, Finland. E-mail: [email protected]
Diabetes 1996;45(3):308–315
Article history
Received:
April 11 1995
Revision Received:
November 03 1995
Accepted:
November 03 1995
PubMed:
8593935
Citation
Jari P Töyry, Leo K Niskanen, Matti J Mäntysaari, Esko A Länsimies, Matti IJ Uusitupa; Occurrence, Predictors, and Clinical Significance of Autonomic Neuropathy in NIDDM: Ten-Year Follow-Up From the Diagnosis. Diabetes 1 March 1996; 45 (3): 308–315. https://doi.org/10.2337/diab.45.3.308
Download citation file: